Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
FOMO Investing
Brian and Mik
The Moneywise Guys
Wealth Management - Community
The Collision Vision
Autobody News
Tech & Co Business
BFM Business
START
Fondo
Charting Wealth's Daily Stock Trading Review
ChartingWealth.com
Fox Business Hourly Report
FOX News Podcasts
Bitcoin News Alerts | Daily BTC Macro Signal
Bitcoin News Alerts
Le journal d'Europe 1
Europe 1
Top of Mind
Gambit Collective
每日聽管理
經理人
Bob Proctor: The Science of Success
Bob Proctor
經理人Podcast
經理人Podcast
The Home Service Expert Podcast
Tommy Mello: $200 Million Founder|Forbes, Inc., Entrepreneur Columnist
Global Economic Press
Global Economic Press
Ca$hMire de Pierre Couture
Pierre Couture
The Heart of Entrepreneurship
Dave Kashen and Jesse Pujji
Finance Exam Prep
Ran Chen, EA, CFP®
The Clinton Donnelly Show
Clinton Donnelly
Skye's The Limit
Skye Estroff
The Build With ICF Podcast
BuildWithICF.com
The Invisible Hand
Emma Reid
Autoblog News
Fannys Förebilder
Fanny Widman
Singing Teachers Talk
BAST Training
Proactive - Interviews for investors
Proactive
Health fitness wealth business podcast series
Clifton pope
Market Updates
Marcus Today
"Your Path To Career Success"
Kathryn Hall "The Career Owl"
Buying and Beyond
Buying & Beyond
The Music Business Buddy
Jonny Amos
Don Draper's Den
Dimalanta Design Group
Becoming a Cut Flower Grower
Lydia Watson
Relocalizing Health with Dave Chase
TopHealth Media
Legally Goff
声动早咖啡
声动活泼
High Voltage Business Builders Podcast
Neil Twa
Business
Brian and Mik
Abivax became one of June 2026's wildest biotech stories: a potential best-in-class drug to treat ulcerative colitis, a scary “cancer” headline, a violent selloff, and then a dramatic rebound after Part 2 safety data hel...
Is SpaceX's $1.75 Trillion IPO more like Project Hail Mary or Interstellar? We unpack the SpaceX IPO from a valuation lens. We synthesize the highly varied perspectives from the ultra bulls (Gavin Baker), the bears (Jim...
Michael Burry is back, and this time the newsletter gang is paying monthly. We explore his shift from hedge fund manager to Cassandra Unchained newsletter writer, the ideas that stood out to us, and his bearish take on N...
Brian and Mik unpack a live activist situation at Humm Group, a small Australian non-bank lender now facing public pressure from investor Jeremy Raper, who owns ~6% of the company and is pushing for a vote on board chang...
In this year-end episode, Brian and Mik reflect on FOMO Investing—its origins, how the podcast has evolved, and where they hope to take it in 2026. They revisit key themes from the past year, including quantum computing ...
After the post-IPO drawdown, we review whether Rivian is worth another look. Rivian's software-first design, the Volkswagen JV, the R2, as well as its own autonomous driver investments, seem to indicate it may be more t...
$15 salads, a 90% drawdown, and a very confused stock market. We explore Sweetgreen as a potential turnaround—what’s broken, what might work, and why demand alone doesn’t save a business. Sometimes the hardest investment...
In this episode of FOMO Investing, Brian and Mik revisit IonQ (IONQ). Building on our original Theory of the Case from November 2024 and our January 2025 update, we unpack recent developments, including:Management change...
OpenAI is racing toward a trillion-dollar valuation while burning tens of billions on chips, data centers, and Azure commitments. We break down the new capital structure, Microsoft’s leverage, why Zuck is FOMO-building c...
The AI & investing episode. Brian and Mik talk about whether AI will actually replace white-collar jobs or just transform them, how professionals can stay relevant by becoming AI-powered specialists, and where value migh...
In this episode, Brian and Mik launch a new segment called “Dealable”—where they set aside strict analysis and let their imaginations run on mergers, acquisitions, partnerships, and spin-outs that should happen (even if ...
(This show was recorded on 31st July 2025)Brian and Mik catch up on a few investment ideas they have been followingWhat we coverANSYS × Synopsys: the deal closed; why a stock-and-cash structure gave us yield and long-ter...
In this episode of FOMO Investing, Brian O’Neill and Mikhail Bulchandani do a deep dive into one of Brian’s favorite stocks, TG Therapeutics (TGTX). Brian outlines his multi-year investment thesis in TGTX, from its setb...
In this episode of FOMO Investing, Brian and Mik dive into the volatile world of Carvana, exploring its business model, recent stock performance, and the ongoing debate between short and long theses. Mik shares his perso...
For the lucky no. 13 episode of FOMO Investing, we explore the powerful yet often misunderstood force of "Fear of Missing Out" (FOMO) in investing. We unpack the psychology behind why investors often feel compelled to a...
In this episode, we develop our Theory Of The Case (TOTC) on the ANSYS + Synopsys merger. We cover the potential upside from the deal. Why ANSYS + Synopsys could be the backbone of Physics AI. The merger arbitrage oppo...
In this episode of FOMO Investing, we dive into the full story of Checkpoint Therapeutics, a microcap biotech that just entered into an agreement to be acquired by Sun Pharma. Brian walks us through his personal “theory ...
An update to our Theory of The Case (TOTC) on IonQ ~ mid-January 2025. We review Jensen Huang's and Mark Zuckerburg's claims about the timeline for useful quantum computing (being 15+ years out). We also include IonQ ma...
In this end-of-year episode, Brian and Mik explore the evolution of Bitcoin—from its mysterious beginnings with Satoshi Nakamoto’s 2008 white paper to its current six-figure price. They discuss how Bitcoin’s role has shi...
In this episode, we unpack the latest developments at Intel following the sudden resignation of CEO Pat Gelsinger. In this Theory Of The Trade (TOTT) episode, we recount why Mik initially started investing in Intel when ...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.